The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jason McCarthy - Maxim Group - Analyst
: Hey, Jim and Clay. Thanks for taking the questions. Just on a technical question, can you talk a little bit about.
So the I think that was a little bit being overlooked by people and that the spindle RNA preliminaries that you acquired wasn't really intended to
do self-amplifying and there was a lot of things that your group had to we leverage its expertise to get it to work on. Can you just talk a little bit
about that and what that means for the self-amplifying aspect of what you're doing in the biotherapeutics world?
Question: Jason McCarthy - Maxim Group - Analyst
: Got it. And you had mentioned on the first IND was approved in the US trends domestically produced DNA. Can you talk a little bit about more a
little more about who that is or what they're working on?
Question: Jason McCarthy - Maxim Group - Analyst
: So can you just last question because I use that for your preclinical, I guess, clientele, you said that 68% of mRNA candidates that are out there are
in the preclinical stage and a bunch of your customers now are in that category, does that IND clearance? Can you leverage out and kind of show
them and kind of pave the way for them to go a little bit deeper with APDN.'s technology and kind of getting yourselves baked into their development
process>
Question: Jason McCarthy - Maxim Group - Analyst
: Great. Thank you, Clay.
Question: Jason McCarthy - Maxim Group - Analyst
: Got it. Thank you, Jim.
Question: Yi Chen - H.C. Wainwright - Analyst
: Thank you for taking my questions. Could you comment on the the revenue for our clinical laboratory service in the fiscal fourth quarter. Do you
think that whether that has reached a baseline level or do you think that could continue to decline in future quarters?
Question: Yi Chen - H.C. Wainwright - Analyst
: And is there a potential time as to whether and when the New York State Department, the House could complete the review process?
Question: Yi Chen - H.C. Wainwright - Analyst
: And would you be able to comment on how many customers have actually ordered from your linear IoT platforms for?
Question: Yi Chen - H.C. Wainwright - Analyst
: Yes.
Question: Yi Chen - H.C. Wainwright - Analyst
: Okay. Do you feel that customer orders from the linear IVT platform could enable the company to demonstrate sequential growth in product and
service revenue going forward.
Question: Yi Chen - H.C. Wainwright - Analyst
: Okay. Last question, could you provide an update at the cash position after September the end of September?
Question: Yi Chen - H.C. Wainwright - Analyst
: $4.5 million? Okay. Thank you.
| 
